Altogether these observations have profound clinical implications, as pharmacological strategies aimed at inhibiting HIF-1α action and/or proteasomal degradation might represent useful strategies for stabilizing ERα expression and sensitize certain sub-populations of breast cancer patients to endocrine therapies [180]. Here, ESR1 is linked to breast cancer.